Watch Ticker

Candel Therapeutics, Inc. Common Stock

Go to Candel Therapeutics, Inc. Common Stock Website

$6.12

-0.19 (-3.01%)

Live

Previous Close

$6.31

Day Range

$6.0802 - $6.375

Previous Day Range

$6.17 - $6.4

Market Cap

$315.1 million USD

Day Vol.

348191

Previous Day Vol.

417604

Currency

USD

Primary Exchange

Nasdaq

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Candel Therapeutics published positive phase 1b clinical trial data on the combination of CAN-2409 and nivolumab plus standard of care in newly diagnosed high-grade glioma patients, demonstrating a promising safety profile and potential survival benefit.

Related tickers: CADL.

Read Full Article

N/A - Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

Candel Therapeutics, a clinical-stage biopharmaceutical company, has appointed Elizabeth M. Jaffee, M.D., a renowned expert in pancreatic cancer and immunology, to its Research Advisory Board. This appointment aligns with Candel's focus on developing multimodal biological immunotherapies for cancer treatment, particularly in borderline resectable pancreatic cancer.

Related tickers: CADL.

Read Full Article

Trending Tickers

Please sign in to view